menu
    • menu
    [{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Acacia Catechu","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aloe Vera","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by KGK Science

    Menu

    KGK Science

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            KGK Science

                            Canada arrow
                            AGGSpend
                            Not Confirmed

                            KGK Science

                            Canada arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Tri...

                            Details : NM-1001 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-a...

                            Product Name : NM-1001

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 18, 2023

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            KGK Science

                            Canada arrow
                            AGGSpend
                            Not Confirmed

                            KGK Science

                            Canada arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Poria Cocos Mushroom Extract,Aloe vera,Rosemary Extract

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrati...

                            Details : UP360 is a naturally-derived extracts from both the Poria cocos mushroom and rosemary as well as Aloe vera gel powder. The UP360 produces antioxidant, anti-inflammatory, and immunomodulatory effects.

                            Product Name : UP360

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 05, 2023

                            Lead Product(s) : Poria Cocos Mushroom Extract,Aloe vera,Rosemary Extract

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            KGK Science

                            Canada arrow
                            AGGSpend
                            Not Confirmed

                            KGK Science

                            Canada arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Ac...

                            Details : Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety eff...

                            Product Name : NM-1001

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 14, 2023

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            KGK Science

                            Canada arrow
                            AGGSpend
                            Not Confirmed

                            KGK Science

                            Canada arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acacia Catechu,Scutellaria Baicalensis

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positiv...

                            Details : UP446, a natural health ingredient developed by Unigen, contains Acacia catechu and Scutellaria baicalensis, botanicals with antioxidant and anti-inflammatory properties; however, this is the first study to examine these ingredients using a human vaccine...

                            Product Name : UP446

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 12, 2022

                            Lead Product(s) : Acacia Catechu,Scutellaria Baicalensis

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth